---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218194"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-05-12T11:35:15+00:00"
generated_at: "2026-05-12T11:42:10.195093+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026

## Summary
- Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.
- Net loss $9.5M vs $13.3M YoY; collaboration revenue $12.6M (up from $2.9M); R&D $19.8M (up from $8.3M).
- Achieved $6.0M development milestone under AbbVie collaboration (Q2 2026).
- XTX501 IND submission planned mid-2026; Phase 1 start H2 2026; initial data H2 2027.
- Appointed Cheryl R. Blanchard, Ph.D. to board of directors (April 2026).

## SEC filing metadata
- accession: 0001193125-26-218194
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-05-12T11:35:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218194
- JSON: https://secwatch.observer/filing/0001193125-26-218194.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218194.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $12.6 million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $12.6 million
  - Result: reported results
  source text: Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, compared to $2.9 million for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.